Related references
Note: Only part of the references are listed.Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study.
M. Terashima et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Pamela L. Kunz et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
HER-2/neu Gene Amplification in Esophageal Adenocarcinoma and Its Influence on Survival
Sarah K. Thompson et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization
Laura J. Tafe et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC).
H. H. Yoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
S. Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
Maria D. Begnami et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+trial of the Arbeitsgemehischaft Internistische Onkologie (AIO)
S. Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
HER-2 amplification is highly homogenous in gastric cancer
Andreas H. Marx et al.
HUMAN PATHOLOGY (2009)
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
S. -E. Al-Batran et al.
ANNALS OF ONCOLOGY (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Significance of HER2 low-level copy gain in Barrett's cancer:: Implications for fluorescence in situ hybridization testing in tissues
Sandra Rauser et al.
CLINICAL CANCER RESEARCH (2007)
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus
Uta Reichelt et al.
MODERN PATHOLOGY (2007)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma:: a tissue microarray study
R. Langer et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
HER 2/neu protein expression in colorectal cancer
B. Schuell et al.
BMC CANCER (2006)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer
I García et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Status of c-erbB-2 in gastric adenocarcinoma:: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay
T Takehana et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.
DG Huntsman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas:: A comparative immunohistochemical and fluorescence in situ hybridization study
N Hirashima et al.
MODERN PATHOLOGY (2001)
Share Paper
